Nov 1 (Reuters) - AstraZeneca PLC:* ASTRAZENECA PLC - ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS* ASTRAZENECA PLC - ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS* ASTRAZENECA: IN Q4 2023, CELLECTIS WILL RECEIVE AN INITIAL PAYMENT OF $105M FROM ASTRAZENECA* ASTRAZENECA: INITIAL EQUITY INVESTMENT OF $80M, AT $5/SHARE, REPRESENTS AN EQUITY STAKE OF
C Plus getuigenissen. 22% IN CELLECTIS
* ASTRAZENECA: A FURTHER $140M EQUITY INVESTMENT, AT $5/SHARE, IS EXPECTED TO CLOSE IN EARLY 2024* ASTRAZENECA: CELLECTIS ALSO ELIGIBLE TO GET IND OPTION FEE, OTHER MILESTONE PAYMENTS, RANGING FROM $70M UP TO $220M PLUS TIERED ROYALTIES Source text for Eikon: Further company coverage: